These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36100788)

  • 21. Insights into White Matter Defect in Huntington's Disease.
    Sun Y; Tong H; Yang T; Liu L; Li XJ; Li S
    Cells; 2022 Oct; 11(21):. PubMed ID: 36359783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The early cellular pathology of Huntington's disease.
    Li XJ
    Mol Neurobiol; 1999; 20(2-3):111-24. PubMed ID: 10966117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implications of the Orb2 Amyloid Structure in Huntington's Disease.
    Hervás R; Murzin AG; Si K
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32967102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
    Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
    Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Focused ultrasound-induced blood brain-barrier opening enhanced vascular permeability for GDNF delivery in Huntington's disease mouse model.
    Lin CY; Tsai CH; Feng LY; Chai WY; Lin CJ; Huang CY; Wei KC; Yeh CK; Chen CM; Liu HL
    Brain Stimul; 2019; 12(5):1143-1150. PubMed ID: 31079989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Is Huntington's disease a neurological or psychiatric disorder? case report].
    Dubas-Slemp H; Tylec A; Michałowska-Marmurowska H; Spychalska K
    Psychiatr Pol; 2012; 46(5):915-22. PubMed ID: 23394029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.
    Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR
    Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging Roles of Exosomes in Huntington's Disease.
    Ananbeh H; Vodicka P; Kupcova Skalnikova H
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of iron imaging in Huntington's disease.
    van den Bogaard SJ; Dumas EM; Roos RA
    Int Rev Neurobiol; 2013; 110():241-50. PubMed ID: 24209441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.
    Nithianantharajah J; Hannan AJ
    Neuroscience; 2013 Oct; 251():66-74. PubMed ID: 22633949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
    Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
    J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease.
    Hannan AJ
    Acta Biochim Pol; 2004; 51(2):415-30. PubMed ID: 15218539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synaptopathic mechanisms of neurodegeneration and dementia: Insights from Huntington's disease.
    Tyebji S; Hannan AJ
    Prog Neurobiol; 2017 Jun; 153():18-45. PubMed ID: 28377290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Faulty splicing and cytoskeleton abnormalities in Huntington's disease.
    Fernández-Nogales M; Santos-Galindo M; Hernández IH; Cabrera JR; Lucas JJ
    Brain Pathol; 2016 Nov; 26(6):772-778. PubMed ID: 27529534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential Transfer of Polyglutamine and CAG-Repeat RNA in Extracellular Vesicles in Huntington's Disease: Background and Evaluation in Cell Culture.
    Zhang X; Abels ER; Redzic JS; Margulis J; Finkbeiner S; Breakefield XO
    Cell Mol Neurobiol; 2016 Apr; 36(3):459-70. PubMed ID: 26951563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic prospects for the prevention of neurodegeneration in Huntington's disease and the polyglutamine repeat disorders.
    Kimura Y; Lee WC; Littleton JT
    Mini Rev Med Chem; 2007 Jan; 7(1):99-106. PubMed ID: 17266642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].
    Bogomazova AN; Eremeev AV; Pozmogova GE; Lagarkova MA
    Mol Biol (Mosk); 2019; 53(6):954-967. PubMed ID: 31876275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges of Huntington's disease and quest for therapeutic biomarkers.
    Kotrcova E; Jarkovska K; Valekova I; Zizkova M; Motlik J; Gadher SJ; Kovarova H
    Proteomics Clin Appl; 2015 Feb; 9(1-2):147-58. PubMed ID: 25290828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring the role of high-mobility group box 1 (HMGB1) protein in the pathogenesis of Huntington's disease.
    Angelopoulou E; Paudel YN; Piperi C
    J Mol Med (Berl); 2020 Mar; 98(3):325-334. PubMed ID: 32036391
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.